Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.

Sep 20, 2024 - 04:00

Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.

Read the original article

Tags:

Previous Article

Biotechs investigate ways to adapt to new clinical trial regulation and economic...

AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Senators interrogate health secretary Becerra on Alzheimer’s drug coverage

STAT+: Senators interrogate health secretary Becerra on...

Mar 22, 2023

Johnson & Johnson gets grant for heart ultrasound image...

Apr 25, 2024

The Senate health committee looks into its first subpoena in 40 years

The Senate health committee looks into its first subpoe...

Jan 20, 2024